More about

Drug Cost

News
August 10, 2021
6 min read
Save

CMS nixes 'most-favored nation' pricing model for Medicare Part B

CMS nixes 'most-favored nation' pricing model for Medicare Part B

CMS plans to rescind a Trump-era interim final rule that would have established a “most-favored nation” pricing model for Medicare Part B drugs, following months of lawsuits that saw the proposal stalled in federal court.

News
July 08, 2021
4 min read
Save

Cancer drug revenues increased by 96% over past decade

Cancer drug revenues increased by 96% over past decade

The oncology drug setting has changed monumentally in recent years, with an unprecedented increase in new therapeutic agents. This surge in drug development is reflected by a 70% increase in clinical trials for new cancer drugs.

News
January 15, 2021
8 min read
Save

Most-favored nation model for Medicare Part B drug reimbursement ‘designed to fail’

Most-favored nation model for Medicare Part B drug reimbursement ‘designed to fail’

A new Trump administration policy aimed at lowering drug prices for Medicare beneficiaries has drawn criticism from the medical community, especially those in the oncology field.

News
October 27, 2020
2 min read
Save

ACR urges UnitedHealthcare to cancel new copay proposal

ACR urges UnitedHealthcare to cancel new copay proposal

The American College of Rheumatology and 11 other provider and patient groups have called on UnitedHealthcare to cancel its proposed copay accumulator initiative, arguing it would increase financial burdens and limit access to treatments.

News
October 09, 2020
3 min read
Save

Should prices of biosimilars be regulated in the US?

Should prices of biosimilars be regulated in the US?

Bringing down the prices of biosimilars in the United States will be a tricky balance. On one hand, you want to be able to make these drugs available to every patient who needs them. On the other hand, just lowering the prices artificially through legislation could stunt innovation and disincentivize companies from bringing these drugs to market.

News
August 26, 2020
3 min read
Save

Patients with lupus more likely to skip doses, delay filling prescriptions due to cost

Patients with lupus more likely to skip doses, delay filling prescriptions due to cost

Patients with systemic lupus erythematosus are more likely than those in the general population to skip doses, take less medicine and delay filling prescriptions due to cost, according to data published in Arthritis Care & Research.

News
July 31, 2020
5 min read
Save

Big pharma and COVID-19: Balancing social commitments and profits

Big pharma and COVID-19: Balancing social commitments and profits

It is quite possible that the attempt to treat COVID-19 will bear out as the peak of pharmaceutical research and development in human history.

News
July 23, 2020
3 min read
Save

Adding colchicine to prevent gout flares while initiating allopurinol 'very cost effective'

Adding colchicine to prevent gout flares while initiating allopurinol 'very cost effective'

Despite its increased cost in the United States, colchicine use to prevent gout flares while starting treatment with allopurinol remains “very cost effective,” according to findings published in Arthritis Care & Research.

News
July 10, 2020
5 min read
Save

Bringing drug costs down a ‘peg’ or two

Bringing drug costs down a ‘peg’ or two

At our center, metrics obtained through our participation in CMS’s Oncology Care Model have allowed us to improve patient experience scores, reduce ED utilization and hospital admission, and impact several other measures of quality care.

News
March 06, 2020
4 min read
Save

Some patients turning to Craigslist for affordable insulin

Some patients turning to Craigslist for affordable insulin

People are using Craigslist to buy and sell lifesaving drugs, particularly insulin, according to a research letter published in JAMA Internal Medicine.

View more